What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

doi:10.3748/wjg.v20.i5.1248

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 5

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5364)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

407

WORD

171

HTML

3210

Figures (1-1)

143

Sum=3931

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

774

Download

659

Sum=1433

Feb 7, 2014 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Feb 7, 2014; 20(5): 1248-1258
Published online Feb 7, 2014. doi: 10.3748/wjg.v20.i5.1248

Open in New Tab Full Size Figure Download Figure

Figure 1 Modification of Leukocyte trafficking by the anti-integrins. VCAM-1: Vascular cell adhesion molecule-1; MAdCAM-1: Mucosal addressin cell adhesion molecule 1.

Citation: Lawrance IC. What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J Gastroenterol 2014; 20(5): 1248-1258
URL: https://www.wjgnet.com/1007-9327/full/v20/i5/1248.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i5.1248